Physician Views: Clinical data for CAR-T therapies in DLBCL grows at ASH

New data presented for Gilead Sciences' Yescarta, Novartis' Kymriah (both marketed) and Juno Therapeutics' JCAR017 (in clinical development) at this week's annual meeting of the American Hematology Society (ASH) has simultaneously strengthened the clinical profile of CAR-T therapy for diffuse large B-cell lymphoma (DLBCL) and hinted at how the commercial landscape of these treatments could evolve.

To gauge reaction to new data and disclosures we are snap-polling US and EU5 oncologists…

Based on new data for CAR-T therapies in DLBCL presented at ASH this weekend, how confident are you that in patients who respond to therapy at 3/6 months (there is now more evidence to show the vast majority of 3 month complete responders remain CRs at six months), CAR-T will provide a durable long-term effect?

Not confident

Slightly confident

Moderately confident

Very confident

Which of these side-effect profiles for CAR-T therapy in DLBCL do you think is most favourable:

  1. 58% rate of cytokine release syndrome (CRS) with 23% classified as grade 3 or 4 (using Penn grading scale) and 21% rate of neurological events with 12% classified as grade 3 or 4; versus
  2. 94% rate of CRS with 13% classified as grade 3 or 4 (using Lee grading system) and 87% rate of neurological events with 31% classified as grade 3 or 4.

a

b

Will depend on characteristics of patient

If serious side effects (i.e. CRS/neurological events) do not occur and the patient can be treated in an outpatient setting, how important could this be in determining whether one CAR-T is used in favour of another?

Not important

Slightly important

Moderately important

Very important

In five years' time, how frequently do you think CAR-T therapies will be used to treat heavily pre-treated DLBCL patients?

Never

Rarely

Sometimes

Often

Always

Do you agree that if responsive DLBCL patients typically remain complete responders to CAR-T therapy over a multiple year period, the efficacy and cost of these therapies (Gilead's Yescarta is list priced at $373,000 in the US) will justify use earlier in the treatment paradigm?

Yes

No

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions. Note: FirstWord Polls are powered by Medefield MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties and over 100 markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

To read more Physician Views articles, click here.